1 Erratum to: Drugs (2015) 75:2035–2043 DOI 10.1007/s40265-015-0494-7
Page 2038, Sect. 2.3.1 Schizophrenia, second paragraph, third sentence, which previously read:
Risperidone 40 mg/day, which was included as an internal control for assay sensitivity, also reduced PANSS total score significantly more than placebo (−26.9 vs. −11.8; p ≤ 0.001).
Should read:
Risperidone 4.0 mg/day, which was included as an internal control for assay sensitivity, also reduced PANSS total score significantly more than placebo (−26.9 vs. −11.8; p ≤ 0.001).
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-015-0494-7.
Rights and permissions
About this article
Cite this article
McCormack, P.L. Erratum to: Cariprazine: First Global Approval. Drugs 76, 419 (2016). https://doi.org/10.1007/s40265-016-0547-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-016-0547-6